Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S.
- Category: More News
- Published on Thursday, 08 March 2018 09:32
- Hits: 666
This marks Zydus' first branded product launch in the U.S. and Medicure's second cardiovascular drug on the U.S. market
AHMEDABAD, India and WINNIPEG, Canada I March 7, 2018 I Zydus Cadila, a leading innovation-driven, global healthcare provider, announced that it has entered into a definitive agreement with Medicure International Inc., a subsidiary of Medicure Inc. (Medicure) to commercialize its 505(b)(2) New Drug Application (NDA) product, pitavastatin magnesium (ZYPITAMAGTM) in the United States. The launch of ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded product launch for Zydus in the U.S.
Medicure is a U.S. pharmaceutical company and has a proven track-record of successful commercialization of products in the therapeutic segments of cardiovascular and metabolic diseases. As a part of this agreement, Zydus will hold the NDA and Medicure will be responsible for the sales and marketing of ZYPITAMAG.
Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Cadila said, "The launch of this proprietary drug is in continuation of our commitment to exploring new pathways in pharmaceutical technology with a thrust on enhancing patient care and well-being. In this endeavour, we are happy to partner with Medicure in reaching out to the patient community and helping them access this NDA for desired health outcomes".
"Medicure is pleased to partner with Zydus Cadila and add ZYPITAMAG to its cardiovascular commercial operation. This partnership fits well with Medicure's mission of being a significant cardiovascular pharmaceutical company focused on the U.S. market," commented Medicure's President and CEO, Dr. Albert D. Friesen.
Approved in strengths of 1 mg, 2 mg and 4 mg, ZYPITAMAG is an HMG-CoA reductase inhibitor indicated for Patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). (Further information is available in the annexure appended below)
About Zydus Cadila
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. For more information, please visit www.zyduscadila.com
Medicure is a pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. cardiovascular market. The primary focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.
SOURCE: Zydus Cadila